BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20299498)

  • 1. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
    Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
    Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
    Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
    J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
    Agarwal PK; Sadetsky N; Konety BR; Resnick MI; Carroll PR;
    Cancer; 2008 Jan; 112(2):307-14. PubMed ID: 18050294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.
    Homma Y; Akaza H; Okada K; Yokoyama M; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 Apr; 11(4):218-24. PubMed ID: 15028100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surgical and medical treatment for localized prostate cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
    Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
    BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.